# A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy

> **NCT01589718** · PHASE3 · WITHDRAWN · sponsor: **Greater Houston Retina Research**

## Conditions studied

- Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** Macugen
- **DRUG:** Sham

## Key facts

- **NCT ID:** NCT01589718
- **Lead sponsor:** Greater Houston Retina Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-04
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients were enrolled
- **Last updated:** 2014-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01589718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01589718, "A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01589718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*